Sept. 23, 2013
/PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the closing of its previously announced underwritten public offering of 6,100,000 shares of its common stock, as well as 915,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.
The shares were sold at the public offering price of
per share, the last closing price of the stock on the date immediately prior to pricing. This brings the aggregate gross proceeds from the offering to approximately
, before deducting underwriting discounts and commissions and other offering expenses.
Lazard Capital Markets LLC, JMP Securities LLC and
& Co. acted as joint book-running managers and Cowen and Company, LLC acted as co-lead manager for the offering.
The shares described above were issued pursuant to a prospectus supplement and accompanying prospectus, all as filed as part of a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission ("SEC"). The company filed a final prospectus supplement relating to the offering with the SEC on
September 19, 2013
, which is available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at
. Copies of the final prospectus supplement and the accompanying prospectus may be obtained by sending a request to: Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor,
New York, NY
10020, or via telephone at 800-542-0970; or JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor,
San Francisco, CA
94111, or via telephone at 415-835-8985; or
& Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
55402, or via telephone at 800-747-3924.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Sangamo, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.